Drugs / BI 2536 BS
last change Mar 2007 re-read 3 minutes ago

BI 2536 BS

Developed for
neoplasm
Investigated by
Boehringer Ingelheim

Trials 1

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02211872 Aug 2004 → Mar 2007 neoplasm Boehringer Ingelheim Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BI 2536 BS ClinicalTrials.gov intervention name — accepted as the source's own label NCT02211872 ↗
Route Intravenous “BI 2536 BS, intravenous” NCT02211872 ↗